CheckMate 227 Induced Manageable Toxicities With Immunotherapy Combination in NSCLC
Suresh Ramalingam, MD, FASCO, discusses the key takeaways regarding the toxicities observed in the phase 3 CheckMate 227 clinical trial, which evaluated immunotherapeutic agents nivolumab plus ipilimumab as treatment of patients with non–small cell lung cancer.
Suresh Ramalingam, MD, FASCO, deputy director, Winship Cancer Institute of Emory University, discusses the key takeaways regarding the toxicities observed in the phase 3 CheckMate 227 clinical trial, which evaluated immunotherapeutic agents nivolumab (Opdivo) plus ipilimumab (Yervoy) as treatment of patients with non–small cell lung cancer (NSCLC).
One question that often comes up regarding combining multiple immunotherapies is whether there is a high incidence of autoimmune toxicity and the impact of that is on patients, Ramalingam says. Based on the long-term data from this trial, most salient toxicities occurred within the first 6 months of treatment and were manageable in the majority of patients.
Beyond the 6-month time period, the likelihood of developing any of these toxicities is relatively low, which shows that with supportive care, patients are able to get through the planned 2 years of therapy. This is reassuring to both the patient and physician, says Ramalingam.
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
AI-Driven Deep Learning Model Shows Promise in Standardizing MDS Diagnosis
December 10th 2024In an interview, Palak Dave discussed how artificial intelligence, using deep learning to analyze bone marrow aspirate smear images, could standardize and accelerate the diagnosis of MDS vs pre-MDS conditions.
Read More
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More
